| 1. | | Suspended | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma |
| 2. | | Recruiting | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 3. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 4. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer |
| 5. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 6. | | Recruiting | 17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma |
| 7. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer |
| 8. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ... |
| 9. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma |
| 10. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ... |
| 11. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 12. | | No longer recruiting | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease |
| 13. | | Recruiting | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Chronic Myelogenous Leukemia; secondary acute myeloid leukemia |
| 14. | | Recruiting | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: acute leukemia; adult acute monoblastic and acute monocytic leukemia; atypical chronic myeloid leukemia; chronic leukemia; ... |
| 15. | | No longer recruiting | 4'-Iodo-4'-deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis |
| 16. | | Completed | 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition: Beta Thalassemia |
| 17. | | Completed | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
Conditions: refractory chronic lymphocytic leukemia; T-cell chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia |
| 18. | | No longer recruiting | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Conditions: Leukemia; Lymphoma; Multiple Myeloma |
| 19. | | No longer recruiting | 506U78 in Treating Patients With Lymphoma
Conditions: Leukemia; Lymphoma |
| 20. | | Suspended | 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
Conditions: recurrent adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ... |
| 21. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Conditions: recurrent cutaneous T-cell lymphoma; recurrent mycosis fungoides/Sezary syndrome |
| 22. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult T-cell leukemia/lymphoma; angioimmunoblastic T-cell lymphoma; ... |
| 23. | | No longer recruiting | 506U78 in Treating Patients With Refractory Hematologic Cancer
Conditions: recurrent childhood lymphoblastic lymphoma; T-cell childhood acute lymphoblastic leukemia; recurrent childhood acute lymphoblastic leukemia |
| 24. | | No longer recruiting | 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: recurrent adult lymphoblastic lymphoma; recurrent adult T-cell leukemia/lymphoma; recurrent childhood lymphoblastic lymphoma; ... |
| 25. | | Recruiting | 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: recurrent adult acute lymphoblastic leukemia; T-cell adult acute lymphoblastic leukemia; recurrent adult lymphoblastic lymphoma |
| 26. | | Completed | 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; recurrent adult acute myeloid leukemia; ... |
| 27. | | Completed | 8-Chloro-cyclic Adenosine Monophosphate in Treating Patients With Recurrent or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm |
| 28. | | No longer recruiting | Acitretin in Treating Patients With Skin Disease or Skin Cancer
Conditions: actinic keratosis; stage III mycosis fungoides/Sezary syndrome; stage IV mycosis fungoides/Sezary syndrome; skin metastases; ... |
| 29. | | Recruiting | Activation and Function of Eosinophils in Conditions with Blood or Tissue Eosinophilia
Conditions: Asthma; Eosinophilia; Helminthiasis; Hypersensitivity; Parasitic Disease |
| 30. | | No longer recruiting | Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Conditions: Graft vs Host Disease; Multiple Myeloma |
| 31. | | No longer recruiting | Active Specific Immunotherapy for Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
Conditions: B Cell Lymphoma; Follicular Lymphoma; Lymphoma |
| 32. | | Recruiting | Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
Conditions: Cancer; oral complications of cancer and cancer therapy; Pain |
| 33. | | Completed | Acute Myeloid Leukemia Study
Condition: Acute Myeloid Leukemia |
| 34. | | Recruiting | Acute Myeloid Leukemia Study
Condition: Acute Myeloid Leukemia |
| 35. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 36. | | Not yet recruiting | Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Recurrent Accelerated or Blast Phase Chronic Myelogenous Leukemia After Undergoing Allogeneic Stem Cell Transplantation
Conditions: accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; ... |
| 37. | | No longer recruiting | AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: refractory plasma cell neoplasm |
| 38. | | Recruiting | AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate
Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 39. | | Recruiting | AG-858 in Patients who are Cytogenetically Positive after Treatment with Gleevec™
Condition: Leukemia, Myeloid, Chronic |
| 40. | | Recruiting | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Conditions: B-cell adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ... |
| 41. | | Recruiting | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome |
| 42. | | Recruiting | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 43. | | Not yet recruiting | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease; Non-Hodgkin's Lymphoma; ... |
| 44. | | Recruiting | Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia; ... |
| 45. | | Recruiting | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
Condition: recurrent childhood acute lymphoblastic leukemia |
| 46. | | Recruiting | Alemtuzumab, Total-Body Irradiation, and Fludarabine Followed By Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer |
| 47. | | Recruiting | Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia |
| 48. | | No longer recruiting | Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes; Chediak-Higashi Syndrome; Common Variable Immunodeficiency; Graft Versus Host Disease; ... |
| 49. | | Recruiting | Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
Condition: recurrent adult Hodgkin's lymphoma |
| 50. | | Completed | Altretamine and Etoposide in Treating Patients With HIV-Related Cancer
Conditions: epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma; AIDS-related peripheral/systemic lymphoma |
